To identify potential biomarkers associated with severe ALD that would distinguish patients with severe ALD from those with non-severe ALD and HC, the model performance of B2M, IGFBP3, and IGFALS was evaluated independently and in combination and was benchmarked against commercially available serum tests for evaluation of liver fibrosis FIB-4 index, AAR, and APRI. This evidence concerns the gene B2M and Hepatic fibrosis.